ADVERTISEMENT

Comments?
Help us improve Portfolio Grader.


Comments?
Help us improve Portfolio Grader.


Blue Chip Growth

Stock Report: "Alnylam Pharmaceuticals, Inc" (ALNY) Report Updated: Aug 18, 2014 | Print This Page

Get more stock ratings by Louis Navellier

"Alnylam Pharmaceuticals, Inc" (ALNY)

Rating: Hold Volatility: Moderate
Total Grade: C Industry: Biotechnology
Competitors: GNVC, DYAX, CBPO, MDVN

Stock Analysis

Rating: Monthly View

A
B
C
D
F
August September October November December January February March April May June July

Rating: Weekly View

This Week: C down no change
Last Week: C same no change
Two Weeks Ago: C up no change
service keys

"Alnylam Pharmaceuticals, Inc"© quotemedia

Company Profile

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, engages in discovering, developing, and commercializing novel therapeutics based on RNA interference (RNAi). Its core product programs under clinical or pre-clinical development include ALN-TTR, a Phase I clinical trial program for the treatment of transthyretin-mediated amyloidosis; ALN-APC, a Phase I clinical trial program for the treatment of hemophilia; ALN-PCS for the treatment of severe hypercholesterolemia; ALN-HPN, a pre-clinical development for the treatment of refractory anemia; and ALN-TMP, a pre-clinical development for the treatment of hemoglobinopathies, including beta-thalassemia and sickle cell anemia. The company’s partner-based programs comprise ALN-RSV01, a Phase II clinical trial program for the treatment of respiratory syncytial virus infection; ALN-VSP, a Phase I clinical trial completed program for the treatment of liver cancers; and ALN-HTT, a pre-clinical development for the treatment of Huntington’s disease. It has strategic alliances with Novartis Pharma AG; F. Hoffmann-La Roche Ltd; Takeda Pharmaceutical Company Limited; Isis Pharmaceuticals, Inc.; Medtronic Inc.; Kyowa Hakko Kirin Co., Ltd.; and Cubist Pharmaceuticals, Inc., as well as strategic collaboration with Ascletis Pharmaceuticals (Hangzhou) Co., Ltd. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Recent News: "Alnylam Pharmaceuticals, Inc"